Insmed (INSM)
NASDAQ: INSM
· Real-Time Price · USD
105.89
0.47 (0.45%)
At close: Jun 24, 2025, 3:59 PM
105.20
-0.65%
After-hours: Jun 24, 2025, 06:07 PM EDT
0.45% (1D)
| Bid | 104.88 |
| Market Cap | 20.11B |
| Revenue (ttm) | 381.03M |
| Net Income (ttm) | -1.01B |
| EPS (ttm) | -5.94 |
| PE Ratio (ttm) | -17.83 |
| Forward PE | -28.07 |
| Analyst | Buy |
| Ask | 106.88 |
| Volume | 3,841,180 |
| Avg. Volume (20D) | 3,049,846 |
| Open | 105.50 |
| Previous Close | 105.42 |
| Day's Range | 104.18 - 106.58 |
| 52-Week Range | 60.40 - 106.58 |
| Beta | 0.79 |
About INSM
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol INSM
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for INSM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Insmed is scheduled to release its earnings on Aug 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+7.75%
Insmed shares are trading higher after the multipl...
Unlock content with
Pro Subscription
2 weeks ago
+28.65%
Insmed shares are trading higher after the company announced topline results from its randomized, double-blind, placebo-controlled Phase 2b study evaluating the efficacy and safety of treprostinil palmitil inhalation powder met its primary endpoint and all secondary efficacy endpoints.
2 weeks ago · https://thefly.com
Liquidia price target lowered by $2 at BofA, here's whyLiquidia -2.845 (-15.80%) Insmed +19.21 (+27.19%) 17 Jun
2 weeks ago · proactiveinvestors.com
Insmed shares surge on positive trial results for pulmonary arterial hypertension therapyInsmed Incorporated (NASDAQ:INSM) shares surged more than 27% after the company unveiled positive results from a Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil ...
